Argent Biopharma Limited has released a press release.
Phase II Clinical Trial on COVID-19 Patients Commenced
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- March Quarterly Activity and Cashflow Report
- Second Ethics Committee Approval for Phase II COVID-19 Trial
- MGC Pharma Secures Commitments for $3.5m Placement
- Successful Research Results for MGC on Glioblastoma
- Phase II Clinical Trial on Patients Diagnosed with COVID-19
Later from Argent Biopharma
- Voluntary Suspension
- Binding Term Sheet Signed for Distribution of ArtemiC
- Ethics Committee Approval for CannEpil Phase IIb Trial
- 3,250 Prescriptions Milestone Surpassed
- Binding Term Sheet for distribution of CannEpil in Israel
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma